^
Association details:
Biomarker:TMB-H
Cancer:Pituitary Gland Carcinoma
Drug:temozolomide (DNA synthesis inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab

Excerpt:
The liver metastasis harbored a somatic mutational burden consistent with alkylator-induced hypermutation that was absent from the treatment-naive tumor. Resistance to temozolomide treatment, acquisition of new oncogenic drivers, and subsequent sensitivity to immunotherapy may be attributed to hypermutation....Combination treatment with ipilimumab and nivolumab may be an effective treatment in pituitary carcinoma.
DOI:
10.1210/jc.2018-01347